254 related articles for article (PubMed ID: 16314484)
1. Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis.
Said N; Motamed K
Am J Pathol; 2005 Dec; 167(6):1739-52. PubMed ID: 16314484
[TBL] [Abstract][Full Text] [Related]
2. Normalization of the ovarian cancer microenvironment by SPARC.
Said N; Socha MJ; Olearczyk JJ; Elmarakby AA; Imig JD; Motamed K
Mol Cancer Res; 2007 Oct; 5(10):1015-30. PubMed ID: 17951402
[TBL] [Abstract][Full Text] [Related]
3. Secreted protein acidic and rich in cysteine (SPARC) inhibits integrin-mediated adhesion and growth factor-dependent survival signaling in ovarian cancer.
Said N; Najwer I; Motamed K
Am J Pathol; 2007 Mar; 170(3):1054-63. PubMed ID: 17322388
[TBL] [Abstract][Full Text] [Related]
4. Secreted protein acidic and rich in cysteine as a regulator of murine ovarian cancer growth and chemosensitivity.
Bull Phelps SL; Carbon J; Miller A; Castro-Rivera E; Arnold S; Brekken RA; Lea JS
Am J Obstet Gynecol; 2009 Feb; 200(2):180.e1-7. PubMed ID: 18992864
[TBL] [Abstract][Full Text] [Related]
5. The impact of the ovarian microenvironment on the anti-tumor effect of SPARC on ovarian cancer.
Greenaway JB; Koehler A; McCulloch CA; Petrik J; Brown TJ; Ringuette MJ
Biochem Cell Biol; 2012 Feb; 90(1):96-107. PubMed ID: 22003835
[TBL] [Abstract][Full Text] [Related]
6. Enhanced angiogenesis characteristic of SPARC-null mice disappears with age.
Reed MJ; Bradshaw AD; Shaw M; Sadoun E; Han N; Ferara N; Funk S; Puolakkainen P; Sage EH
J Cell Physiol; 2005 Sep; 204(3):800-7. PubMed ID: 15795937
[TBL] [Abstract][Full Text] [Related]
7. SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells.
Yiu GK; Chan WY; Ng SW; Chan PS; Cheung KK; Berkowitz RS; Mok SC
Am J Pathol; 2001 Aug; 159(2):609-22. PubMed ID: 11485919
[TBL] [Abstract][Full Text] [Related]
8. SPARC inhibits LPA-mediated mesothelial-ovarian cancer cell crosstalk.
Said NA; Najwer I; Socha MJ; Fulton DJ; Mok SC; Motamed K
Neoplasia; 2007 Jan; 9(1):23-35. PubMed ID: 17325741
[TBL] [Abstract][Full Text] [Related]
9. SPARC is a key regulator of proliferation, apoptosis and invasion in human ovarian cancer.
Chen J; Wang M; Xi B; Xue J; He D; Zhang J; Zhao Y
PLoS One; 2012; 7(8):e42413. PubMed ID: 22879971
[TBL] [Abstract][Full Text] [Related]
10. Compromised production of extracellular matrix in mice lacking secreted protein, acidic and rich in cysteine (SPARC) leads to a reduced foreign body reaction to implanted biomaterials.
Puolakkainen P; Bradshaw AD; Kyriakides TR; Reed M; Brekken R; Wight T; Bornstein P; Ratner B; Sage EH
Am J Pathol; 2003 Feb; 162(2):627-35. PubMed ID: 12547720
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
[TBL] [Abstract][Full Text] [Related]
12. Lenses of SPARC-null mice exhibit an abnormal cell surface-basement membrane interface.
Norose K; Lo WK; Clark JI; Sage EH; Howe CC
Exp Eye Res; 2000 Sep; 71(3):295-307. PubMed ID: 10973738
[TBL] [Abstract][Full Text] [Related]
13. Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM.
Brekken RA; Puolakkainen P; Graves DC; Workman G; Lubkin SR; Sage EH
J Clin Invest; 2003 Feb; 111(4):487-95. PubMed ID: 12588887
[TBL] [Abstract][Full Text] [Related]
14. Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGFβ activation.
Arnold SA; Rivera LB; Carbon JG; Toombs JE; Chang CL; Bradshaw AD; Brekken RA
PLoS One; 2012; 7(2):e31384. PubMed ID: 22348081
[TBL] [Abstract][Full Text] [Related]
15. SPARC ameliorates ovarian cancer-associated inflammation.
Said NA; Elmarakby AA; Imig JD; Fulton DJ; Motamed K
Neoplasia; 2008 Oct; 10(10):1092-104. PubMed ID: 18813349
[TBL] [Abstract][Full Text] [Related]
16. Regulation of the bi-directional cross-talk between ovarian cancer cells and adipocytes by SPARC.
John B; Naczki C; Patel C; Ghoneum A; Qasem S; Salih Z; Said N
Oncogene; 2019 May; 38(22):4366-4383. PubMed ID: 30765860
[TBL] [Abstract][Full Text] [Related]
17. SPARC deficiency results in improved surgical survival in a novel mouse model of glaucoma filtration surgery.
Seet LF; Su R; Barathi VA; Lee WS; Poh R; Heng YM; Manser E; Vithana EN; Aung T; Weaver M; Sage EH; Wong TT
PLoS One; 2010 Feb; 5(2):e9415. PubMed ID: 20195533
[TBL] [Abstract][Full Text] [Related]
18. Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis.
Puolakkainen PA; Brekken RA; Muneer S; Sage EH
Mol Cancer Res; 2004 Apr; 2(4):215-24. PubMed ID: 15140943
[TBL] [Abstract][Full Text] [Related]
19. Loss of insulin-like growth factor I receptor-dependent expression of p107 and cyclin A in cells that lack the extracellular matrix protein secreted protein acidic and rich in cysteine.
Basu A; Rodeck U; Prendergast GC; Howe CC
Cell Growth Differ; 1999 Nov; 10(11):721-8. PubMed ID: 10593648
[TBL] [Abstract][Full Text] [Related]
20. Alterations in SPARC and VEGF immunoreactivity in epithelial ovarian cancer.
Paley PJ; Goff BA; Gown AM; Greer BE; Sage EH
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):336-41. PubMed ID: 10985890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
